Login to Your Account



Kancera lines up fractalkine inhibitor in immuno-oncology

By Cormac Sheridan
Staff Writer

Wednesday, November 11, 2015

Swedish oncology firm Kancera AB is reorienting a drug development program originally conceived for multiple sclerosis toward cancer.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription